Subgroup analysis of treatment-specific SNPs associated with recurrence or survival in surgery-only and surgery-plus-chemotherapy patients for the combined group (discovery plus validation sets)
| Gene-SNP by outcome | Location | Model | Surgery only | Surgery plus chemotherapy | Group† | ||
| HR (95% CI)* | P value | HR (95% CI)* | P value | ||||
| Recurrence | |||||||
| VAV2: rs491220‡ | 3‘UTR | REC | 2.12 (1.29 to 3.50) | 3.06E-03 | 0.30 (0.11 to 0.83) | 1.99E-02 | 1 |
| IFNGR2: rs1059293 | 3‘UTR | REC | 0.45 (0.22 to 0.94) | 3.42E-02 | 2.94 (1.34 to 6.43) | 7.07E-03 | 2 |
| TRA: rs2049787 | 3‘UTR | REC | 1.93 (1.08 to 3.45) | 2.72E-02 | 5.79 (1.75 to 19.1) | 4.02E-03 | 3 |
| PTPRC: rs2359952 | Intron | REC | 1.88 (1.01 to 3.49) | 4.57E-02 | 4.43 (1.71 to 11.5) | 2.19E-03 | 3 |
| NRAS: rs10489525 | Intron | DOM | 0.59 (0.38 to 0.93) | 2.15E-02 | 0.42 (0.19 to 0.92) | 3.05E-02 | 4 |
| Survival | |||||||
| TRB: rs10231513 | Intron | DOM | 2.02 (1.30 to 3.14) | 1.66E-03 | 0.35 (0.15 to 0.81) | 1.36E-02 | 1 |
| STAT4: rs3024896 | Intron | DOM | 1.46 (1.01 to 2.10) | 4.17E-02 | 0.27 (0.08 to 0.94) | 3.95E-02 | 1 |
| PTK2B: rs2322718 | Intron | REC | 1.53 (1.01 to 2.33) | 4.62E-02 | 0.16 (0.04 to 0.71) | 1.57E-02 | 1 |
| MAP3K1: rs12655019 | Intron | DOM | 0.46 (0.27 to 0.79) | 4.96E-03 | 2.71 (1.05 to 6.99) | 3.94E-02 | 2 |
| CUL1: rs243511‡ | Intron | ADD | 0.72 (0.56 to 0.92) | 7.62E-03 | 2.20 (1.10 to 4.41) | 2.62E-02 | 2 |
| VAV2: rs2797826 | Intron | DOM | 0.68 (0.48 to 0.99) | 4.64E-02 | 0.37 (0.16 to 0.82) | 1.53E-02 | 4 |
*HR was adjusted for gender, age, smoking status, tumor stage, performance status.
†Group 1 SNPs are associated with increased recurrence or death risk in surgery-only patients, but reduced risk in surgery-plus-chemotherapy patients. Group 2 SNPs are associated with reduced recurrence or death risk in surgery-only patients, but increased risk in surgery-plus-chemotherapy patients. Group three indicates SNPs associated with increased recurrence/death risk in both treatment groups, while group 4 SNPs are associated with reduced risk in both treatment groups.
‡Rs521446 and rs243519 were linked with rs491220 and rs243511 (r2=1), respectively; thus the data for linked SNPs were not shown.
ADD, additive; DOM, dominant; REC, recessive; SNPs, single-nucleotide polymorphisms.